Global Glucose Excipient Market Size, Share, and Trends Analysis Report, By Type (Anhydrous Glucose, and Glucose Monohydrate), and By Application (Parenteral Nutrition, Dialysis Application, and Injectables), Forecast (2022-2028)

The glucose excipient market is anticipated to grow at a significant CAGR of 4.5% during the forecast period (2022-2028). Glucose excipients play a significant role in medication compositions. Excipients are materials that are used in dosage forms to improve or change the therapeutic impact of medicine. Excipients, on the whole, are inactive substances. Glucose is a common pharmaceutical excipient that is utilized in a variety of formulations. Glucose functions as an excipient by functioning as an osmotic agent, a binder, a sweetening agent, a syrup base, and a parenteral formulation base. The use of appropriate excipients improves patient compliance. The major factors driving the growth of the global glucose excipient market include increasing use in pharmaceutical formulations, especially to mask the unpleasant taste and odor of drug products.

 

 

The global glucose excipient market is segmented based on type and application. Based on type, the market is sub-segmented into anhydrous glucose and glucose monohydrate. Based on application, the market is sub-segmented into parenteral nutrition, dialysis application, and injectables. Among these applications, the parenteral nutrition segment is expected to propel the growth of the market due to the increasing usage of dextrose glucose in the manufacturing of medical injections. For instance, paracetamol syrup and simple linctus medicines are prepared with the use of pharmaceutical-grade dextrose glucose.

 

 

The market players are also contributing significantly to the market’s growth by adopting various strategies, including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in June 2020, Eli Lilly received USFDA approval for Lyumjev, a novel rapid-acting insulin intended to enhance glycemic control in people with type 1 and type 2 diabetes. Lyumjev is a new insulin lispro formulation that has been created to improve insulin absorption and lower A1C readings. Lyumjev regulates high blood sugar levels after meals in individuals with diabetes as a rapid-acting mealtime insulin, similar to how natural insulin acts after meals in persons without diabetes.

 

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape-Cargill India Pvt. Ltd., Archer Daniels Midland Co., Ingredion Inc., Tereos India Pvt. Ltd., Roquette Freres SA, and Qinhuangdao LiHua Starch Co. Ltd., among others.

 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global Glucose Excipient Market Report by Segment

By Type

• Anhydrous Glucose
• Glucose Monohydrate

By Application

• Parenteral Nutrition
• Dialysis Application
• Injectables

 

Global Glucose Excipient Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa